يعرض 1,781 - 1,800 نتائج من 13,395 نتيجة بحث عن '(( significant increase decrease ) OR ( significant ((point decrease) OR (nn decrease)) ))', وقت الاستعلام: 0.35s تنقيح النتائج
  1. 1781
  2. 1782
  3. 1783
  4. 1784
  5. 1785
  6. 1786

    Initial participants by wave*. حسب Yeo Ju Sohn (18536198)

    منشور في 2024
    الموضوعات:
  7. 1787
  8. 1788
  9. 1789
  10. 1790
  11. 1791
  12. 1792
  13. 1793
  14. 1794

    CHAMPS pilot Hb dataset. حسب Jeanie du Toit (20721918)

    منشور في 2025
    "…Postmortem testing showed a significant decrease in hemoglobin concentrations compared to antemortem levels. …"
  15. 1795
  16. 1796

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  17. 1797

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  18. 1798

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  19. 1799
  20. 1800